## LAPORECHIVETO 22 DEC 2005

## PATENT APPLICATION

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q92245

Kazuyuki OHMOTO, et al.

Appln. No.: National Stage Entry of PCT/JP2004/009071

Confirmation No.: Unknown Group Art Unit: Unknown

Filed: December 22, 2005 Examiner: Unknown

For: NOVEL TRICYCLIC HETEROCYCLIC RING COMPOUND

## INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §§ 1.97 and 1.98

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

A copy of an International Search Report in a counterpart application is submitted herewith. The USPTO should receive copies of the references cited in the International Search Report from the International Bureau. Applicant will furnish any missing references upon request. In compliance with the concise explanation of relevance requirement for any foreign language documents listed, Applicants respectfully rely on the information in the International Search Report.

10/561973 IAP9 Recd PCTAPTO 22 DEC 2005

INFORMATION DISCLOSURE STATEMENT National Stage Entry of PCT/JP2004/009071

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after filing a request for continued examination (RCE) under §1.114, and therefore, no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account. A duplicate copy of this paper is attached.

Respectfully submitted,

Much Bolan

SUGHRUE MION, PLLC

Telephone: (202) 293-7060

Facsimile: (202) 293-7860
WASHINGTON OFFICE

23373
CUSTOMER NUMBER

Date: December 22, 2005

Registration No. 32,197

Mark Boland

MODIFIED PTO/SB/08 A & B (06-03)

Substitute for Form 1449 A & B/PTO National Stage Entry Application Number PCT/JP2004/009071 INFORMATION DISCLOSURE Confirmation Number Unknown STATEMENT BY APPLICANT December 22, 2005 Filing Date First Named Inventor Kazuyuki OHMOTO (use as many sheets as necessary) Unknown Art Unit **Examiner Name** Unknown Q92245 Sheet Attorney Docket Number

			U.S.	PATENT DOCUM	ENTS
		Docur	ment Number		
Examiner Initials*	Cite No. <sup>1</sup>	Number	Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		US			
		US			
		US			

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Foreign Patent Document			Publication Date	Name of Patentee or	
		Country Code <sup>3</sup>	Number⁴	Kind Code <sup>5</sup> (if known)	MM-DD-YYYY	Applicant of Cited Document	Translation <sup>6</sup>
	-	JP	2001-072679	Α	03-21-2001	ADIR ET CO.	
		WO	2002/053565	A1	07-11-2002	ONO PHARMACEUTICAL CO., LTD.	
		GB	1444980	A	08-04-1976	VSESOJUZNY NAUCHNOISSLEDOVATELSKY KHIMIKO-FARM ATSEVTICHESKY INSTITUT IMENIS. ORDZHONIKIDZE	
		wo	2002/081471	Al	10-17-2002	NOVARTIS-ERFINDUNGEN VERWALTUNGSGESELLSCHAFT M.B.H.	
		wo	2002/064590	A2	08-22-2002	LILLY ICOS LLC	
		wo	2002/064591	A2	08-22-2002	LILLY ICOS LLC	
		wo	2001/087038	A2	11-22-2001	ORTHO-MCNEILL PHARMACEUTICAL, INC.	
ï		wo	97/43287	A1	11-20-1997	ICOS CORP.	1
		wo	2002/088123	A1	11-07-2002	LILLY ICOS LLC	
		JP	09-508113	Α	08-19-1997	LABORATOIRES GLAXO WELCOME S.A.	
		wo	2003/068753	Al	08-21-2003	ONO PHARMACEUTICAL CO., LTD.	

Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published	
		International Search Report dated October 5, 2004	
		Haishan WANG, et al., "Synthesis and Evaluation of Tryprostatin B and Demethoxyfumitremorgin C Analogues", Journal of Medicinal Chemistry, 2000, Vol. 43, No. 8, Pages 1577-1585	
		Brian E. LOVE, et al., "Preparation of 1-Aryl-β-carbolines", Journal of Organic Chemistry, 1994, Vol. 59, No. 11, Pages 3219-3222	
			ļ — — — — — — — — — — — — — — — — — — —

Examiner Signature	Date Considered	d

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>3</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to indicate here if English language Translation is attached.